Abstract
Coagulopathy is a unique component of the pathology of acute promyelocytic leukaemia (APL). Though many causative factors have been elucidated, therapies to rectify the coagulopathy are far from being realised. Thrombotic and bleeding complications remain the major causes of early deaths. In this chapter, the known causes of abnormalities in haemostatic function, namely the coagulopathy and changes in the fibrinolytic system, will be reviewed. Major risk factors for these complications are identified. Current available measures for correction of the coagulopathy and their effectiveness are critically examined. Unless the coagulopathy can be effectively controlled, bleeding complications will remain an obstacle to achieving a cure for this disease. The issues that need to be addressed in next phase of investigations are also discussed.
Original language | English (US) |
---|---|
Pages (from-to) | 11-18 |
Number of pages | 8 |
Journal | Best Practice and Research: Clinical Haematology |
Volume | 27 |
Issue number | 1 |
DOIs | |
State | Published - Mar 2014 |
Keywords
- acute promyelocytic leukaemia
- bleeding
- fibrinolysis
- thrombosis
- tissue factor
ASJC Scopus subject areas
- Oncology
- Clinical Biochemistry